Skip to main content

Table 1 Genetically modified recombinant clostridial strains and their antitumour studies.

From: Clostridial spores as live 'Trojan horse' vectors for cancer gene therapy: comparison with viral delivery systems

Recombinant Strain

Model

Strategy/Result

Reference

C. oncolyticum/sporogenesrecombinant for E. coli colicin E3

In vitro study

Cancerostatic properties

[56]

C. beijerinckii (acetobutylicum) recombinant for E. coli cytosine deaminase (CDase)

In vitro study and tested on murine EMT6 carcinoma cell-line

Sensitivity to 5-fluorocytosine increased 500-fold

[72]

C. beijerinckii (acetobutylicum) recombinant for Nitroreductase (NTR)

EMT6 Mouse

Prodrug: CB1954

CDEPT strategy with CB1954

Nitroreductase activity detected in tumor lysate

[54]

C. acetobutylicum recombinant for Tumour necrosis factor (TNF-α)

Rhabdomyosarcoma

Recombinant protein detected in tumour, but no control of tumour growth

[58]

C. acetobutylicum recombinant for E. coli cytosine deaminase (CDase)

Rhabdomyosarcoma

Prodrug: 5-FC

CDEPT strategy

Cytosine deaminase activity detected in tumor lysate

[64]

C. sporogenes recombinant for cytosine deaminase (CDase)

SCCVII tumours into syngeneic C3H/Km mice

Prodrug 5-FC

Growth delay of tumours

[57]

C. acetobutylicum recombinant for interleukin-2 (IL-2)

Rhabdomyosarcoma

Enhanced antitumour effect

[60

C. sporogenes and C. novyi-NT recombinant for Nitroreductase (NTR)

Human colorectal carcinoma (HCT116)

CDEPT strategy with CB1954

High level of colonization 108–109 cfu/g tumour.

Repeated CDEPT treatment cycle, significant tumour growth delay

[61]

  1. Description of additional data files (N/A)